{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T14:53:04Z","timestamp":1786719184813,"version":"build-2736575974"},"reference-count":77,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Heart Views"],"published-print":{"date-parts":[[2018]]},"DOI":"10.4103\/heartviews.heartviews_18_18","type":"journal-article","created":{"date-parts":[[2019,3,15]],"date-time":"2019-03-15T08:20:19Z","timestamp":1552638019000},"page":"88","source":"Crossref","is-referenced-by-count":18,"title":["Ranolazine: Multifaceted role beyond coronary artery disease, a recent perspective"],"prefix":"10.4103","volume":"19","author":[{"given":"GopalChandra","family":"Ghosh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"RaktimKumar","family":"Ghosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dhrubajyoti","family":"Bandyopadhyay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krishnarpan","family":"Chatterjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish","family":"Aneja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"key-10.4103\/1995-705X.254347-1","first-page":"2949","volume-title":"2013 ESC guidelines on the management of stable coronary artery disease: The Task Force on the Management of Stable Coronary Artery Disease of the European Society of Cardiology","author":"Task","year":"2013","journal-title":"Eur Heart J"},{"key":"key-10.4103\/1995-705X.254347-2","first-page":"e354","volume-title":"2012 ACCF\/AHA\/ACP\/AATS\/PCNA\/SCAI\/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: A Report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons","author":"Fihn","year":"2012","journal-title":"Circulation"},{"key":"key-10.4103\/1995-705X.254347-3","first-page":"556","volume-title":"Role of ranolazine in cardiovascular disease and diabetes: Exploring beyond angina","author":"Banerjee","year":"2017","journal-title":"Int J Cardiol"},{"key":"key-10.4103\/1995-705X.254347-4","unstructured":"Gilead Sciences, RANEXA\u00ae\u2013Prescribing Information; 2016. Available from: http:\/\/www.gilead.com\/~\/media\/Files\/pdfs\/medicines\/cardiovascular\/ranexa\/ranexa_pi.ashx. [Last accessed on 2017 Jul 10]."},{"key":"key-10.4103\/1995-705X.254347-5","first-page":"469","volume-title":"Clinical pharmacokinetics of ranolazine","author":"Jerling","year":"2006","journal-title":"Clin Pharmacokinet"},{"key":"key-10.4103\/1995-705X.254347-6","first-page":"954","volume-title":"Late sodium current inhibition as a new cardioprotective approach","author":"Hale","year":"2008","journal-title":"J Mol Cell Cardiol"},{"key":"key-10.4103\/1995-705X.254347-7","first-page":"3545","volume-title":"Blockade of Na+channels in pancreatic \u03b1-cells has antidiabetic effects","author":"Dhalla","year":"2014","journal-title":"Diabetes"},{"key":"key-10.4103\/1995-705X.254347-8","first-page":"50","volume-title":"Ranolazine increases \u03b2-cell survival and improves glucose homeostasis in low-dose streptozotocin-induced diabetes in mice","author":"Ning","year":"2011","journal-title":"J Pharmacol Exp Ther"},{"key":"key-10.4103\/1995-705X.254347-9","first-page":"641","volume-title":"Ranolazine: A new approach to treating an old problem","author":"Reddy","year":"2010","journal-title":"Tex Heart Inst J"},{"key":"key-10.4103\/1995-705X.254347-10","first-page":"1375","volume-title":"Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina","author":"Chaitman","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"key-10.4103\/1995-705X.254347-11","first-page":"309","volume-title":"Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: A randomized controlled trial","author":"Chaitman","year":"2004","journal-title":"JAMA"},{"key":"key-10.4103\/1995-705X.254347-12","first-page":"566","volume-title":"Antianginal efficacy of ranolazine when added to treatment with amlodipine: The ERICA (Efficacy of Ranolazine in Chronic Angina) trial","author":"Stone","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"key-10.4103\/1995-705X.254347-13","first-page":"904","volume-title":"Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties","author":"Antzelevitch","year":"2004","journal-title":"Circulation"},{"key":"key-10.4103\/1995-705X.254347-14","first-page":"608","volume-title":"Pathophysiology of the cardiac late na current and its potential as a drug target","author":"Moreno","year":"2012","journal-title":"J Mol Cell Cardiol"},{"key":"key-10.4103\/1995-705X.254347-15","first-page":"1657","volume-title":"Atrial-ventricular differences in rabbit cardiac voltage-gated Na+currents: Basis for atrial-selective block by ranolazine","author":"Caves","year":"2017","journal-title":"Heart Rhythm"},{"key":"key-10.4103\/1995-705X.254347-16","first-page":"7","volume-title":"Ranolazine improves oxidative stress and mitochondrial function in the atrium of acetylcholine-CaCl2 induced atrial fibrillation rats","author":"Zou","year":"2016","journal-title":"Life Sci"},{"key":"key-10.4103\/1995-705X.254347-17","first-page":"69231","volume-title":"Fibroblast growth factor 23 dysregulates late sodium current and calcium homeostasis with enhanced arrhythmogenesis in pulmonary vein cardiomyocytes","author":"Huang","year":"2016","journal-title":"Oncotarget"},{"key":"key-10.4103\/1995-705X.254347-18","first-page":"26","volume-title":"Antiarrhythmic effects of combining dofetilide and ranolazine in a model of acutely induced atrial fibrillation in horses","author":"Carstensen","year":"2018","journal-title":"J Cardiovasc Pharmacol"},{"key":"key-10.4103\/1995-705X.254347-19","first-page":"663","volume-title":"Comparison of vernakalant and ranolazine in atrial fibrillation","author":"Frommeyer","year":"2017","journal-title":"J Cardiovasc Med (Hagerstown)"},{"key":"key-10.4103\/1995-705X.254347-20","first-page":"329","volume-title":"Combined actions of ivabradine and ranolazine reduce ventricular rate during atrial fibrillation","author":"Verrier","year":"2015","journal-title":"J Cardiovasc Electrophysiol"},{"key":"key-10.4103\/1995-705X.254347-21","first-page":"627","volume-title":"Ranolazine effectively suppresses atrial fibrillation in the setting of heart failure","author":"Burashnikov","year":"2014","journal-title":"Circ Heart Fail"},{"key":"key-10.4103\/1995-705X.254347-22","first-page":"2508","volume-title":"Selective late INa inhibition by GS-458967 exerts parallel suppression of catecholamine-induced hemodynamically significant ventricular tachycardia and T-wave alternans in an intact porcine model","author":"Alves","year":"2015","journal-title":"Heart Rhythm"},{"key":"key-10.4103\/1995-705X.254347-23","first-page":"192","volume-title":"First direct comparison of the late sodium current blocker ranolazine to established antiarrhythmic agents in an ischemia\/reperfusion model","author":"Kloner","year":"2011","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"key-10.4103\/1995-705X.254347-24","first-page":"599","volume-title":"Antiarrhythmic effects of ranolazine in a guinea pig in vitro model of long-QT syndrome","author":"Wu","year":"2004","journal-title":"J Pharmacol Exp Ther"},{"key":"key-10.4103\/1995-705X.254347-25","first-page":"953","volume-title":"Ranolazine stabilizes cardiac ryanodine receptors: A novel mechanism for the suppression of early afterdepolarization and torsades de pointes in long QT type 2","author":"Parikh","year":"2012","journal-title":"Heart Rhythm"},{"key":"key-10.4103\/1995-705X.254347-26","first-page":"1647","volume-title":"Effect of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of arrhythmias in patients with non ST-segment elevation acute coronary syndrome: Results from the metabolic efficiency with ranolazine for less ischemia in non ST-elevation acute coronary syndrome thrombolysis in myocardial infarction 36 (MERLIN-TIMI 36) randomized controlled trial","author":"Scirica","year":"2007","journal-title":"Circulation"},{"key":"key-10.4103\/1995-705X.254347-27","doi-asserted-by":"crossref","unstructured":"Weisz G, Farzaneh-Far R, Ben-Yehuda O, Debruyne B, Montalescot G, Lerman A, et al. Use of ranolazine in patients with incomplete revascularization after percutaneous coronary intervention: Design and rationale of the Ranolazine for Incomplete Vessel Revascularization Post-Percutaneous Coronary Intervention (RIVER-PCI) trial. Am Heart J 2013;166:953-9.e3.","DOI":"10.1016\/j.ahj.2013.08.004"},{"key":"key-10.4103\/1995-705X.254347-28","first-page":"940","volume-title":"The effects of ranolazine on paroxysmal atrial fibrillation in patients with coronary artery disease: A preliminary observational study","author":"Leftheriotis","year":"2014","journal-title":"J Atr Fibrillation"},{"key":"key-10.4103\/1995-705X.254347-29","first-page":"872","volume-title":"Ranolazine in the treatment of atrial fibrillation: Results of the dose-ranging RAFFAELLO (Ranolazine in Atrial Fibrillation Following an ELectricaL CardiOversion) study","author":"De","year":"2015","journal-title":"Heart Rhythm"},{"key":"key-10.4103\/1995-705X.254347-30","first-page":"973","volume-title":"Ranolazine enhances the efficacy of amiodarone for conversion of recent-onset atrial fibrillation","author":"Koskinas","year":"2014","journal-title":"Europace"},{"key":"key-10.4103\/1995-705X.254347-31","first-page":"372","volume-title":"Ranolazine added to amiodarone facilitates earlier conversion of atrial fibrillation compared to amiodarone-only therapy","author":"Tsanaxidis","year":"2017","journal-title":"Pacing Clin Electrophysiol"},{"key":"key-10.4103\/1995-705X.254347-32","first-page":"349","volume-title":"Antiarrhythmic effects of ranolazine used both alone for prevention of atrial fibrillation and as an add-on to intravenous amiodarone for its pharmacological cardioversion: A meta-analysis","author":"De","year":"2018","journal-title":"Minerva Cardioangiol"},{"key":"key-10.4103\/1995-705X.254347-33","first-page":"284","volume-title":"Ranolazine for rhythm control in atrial fibrillation: A systematic review and meta-analysis","author":"Guerra","year":"2017","journal-title":"Int J Cardiol"},{"key":"key-10.4103\/1995-705X.254347-34","first-page":"1048","volume-title":"The HARMONY trial: Combined ranolazine and dronedarone in the management of paroxysmal atrial fibrillation: Mechanistic and therapeutic synergism","author":"Reiffel","year":"2015","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"key-10.4103\/1995-705X.254347-35","first-page":"95","volume-title":"The combined effects of ranolazine and dronedarone on human atrial and ventricular electrophysiology","author":"Hartmann","year":"2016","journal-title":"J Mol Cell Cardiol"},{"key":"key-10.4103\/1995-705X.254347-36","first-page":"294","volume-title":"Ranolazine enhances the antiarrhythmic activity of amiodarone by accelerating conversion of new-onset atrial fibrillation after cardiac surgery","author":"Simopoulos","year":"2014","journal-title":"Angiology"},{"key":"key-10.4103\/1995-705X.254347-37","first-page":"673","volume-title":"Comparison of effectiveness and safety of ranolazine versus amiodarone for preventing atrial fibrillation after coronary artery bypass grafting","author":"Miles","year":"2011","journal-title":"Am J Cardiol"},{"key":"key-10.4103\/1995-705X.254347-38","first-page":"733","volume-title":"Ranolazine versus amiodarone for prevention of postoperative atrial fibrillation","author":"Burashnikov","year":"2011","journal-title":"Future Cardiol"},{"key":"key-10.4103\/1995-705X.254347-39","first-page":"988","volume-title":"Effect of ranolazine in preventing postoperative atrial fibrillation in patients undergoing coronary revascularization surgery","author":"Tagarakis","year":"2013","journal-title":"Curr Vasc Pharmacol"},{"key":"key-10.4103\/1995-705X.254347-40","first-page":"410","volume-title":"Short-course of ranolazine prevents postoperative atrial fibrillation following coronary artery bypass grafting and valve surgeries","author":"Hammond","year":"2015","journal-title":"Clin Res Cardiol"},{"key":"key-10.4103\/1995-705X.254347-41","unstructured":"Ranolazine Implantable Cardioverter-Defibrillator Trial (RAID). Available from: https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01215253. [Last accessed on 2017 Oct 29]."},{"key":"key-10.4103\/1995-705X.254347-42","first-page":"1289","volume-title":"Ranolazine shortens repolarization in patients with sustained inward sodium current due to type-3 long-QT syndrome","author":"Moss","year":"2008","journal-title":"J Cardiovasc Electrophysiol"},{"key":"key-10.4103\/1995-705X.254347-43","first-page":"45","volume-title":"Cardioprotective effect of ranolazine in the process of ischemia-reperfusion in adult rat cardiomyocytes","author":"Calder\u00f3n-S\u00e1nchez","year":"2016","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"key":"key-10.4103\/1995-705X.254347-44","first-page":"469","volume-title":"Ranolazine treatment for myocardial infarction.Effects on the development of necrosis, left ventricular function and arrhythmias in experimental models?","author":"Hale","year":"2014","journal-title":"Cardiovasc Drugs Ther"},{"key":"key-10.4103\/1995-705X.254347-45","first-page":"136","volume-title":"Ranolazine in patients with incomplete revascularisation after percutaneous coronary intervention (RIVER-PCI): A multicentre, randomised, double-blind, placebo-controlled trial","author":"Weisz","year":"2016","journal-title":"Lancet"},{"key":"key-10.4103\/1995-705X.254347-46","first-page":"39","volume-title":"Effects of ranolazine on angina and quality of life after percutaneous coronary intervention with incomplete revascularization: Results from the ranolazine for incomplete vessel revascularization (RIVER-PCI) trial","author":"Alexander","year":"2016","journal-title":"Circulation"},{"key":"key-10.4103\/1995-705X.254347-47","first-page":"H1068","volume-title":"Inhibition of the late sodium current slows t-tubule disruption during the progression of hypertensive heart disease in the rat","author":"Aistrup","year":"2013","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"key-10.4103\/1995-705X.254347-48","first-page":"7","volume-title":"Reduced immunoreactivities of B-type natriuretic peptide in pulmonary arterial hypertension rats after ranolazine treatment","author":"Lee","year":"2016","journal-title":"Anat Cell Biol"},{"key":"key-10.4103\/1995-705X.254347-49","first-page":"37","volume-title":"Ranolazine prevents INaL enhancement and blunts myocardial remodelling in a model of pulmonary hypertension","author":"Rocchetti","year":"2014","journal-title":"Cardiovasc Res"},{"key":"key-10.4103\/1995-705X.254347-50","first-page":"691","volume-title":"Phase I safety study of ranolazine in pulmonary arterial hypertension","author":"Gomberg-Maitland","year":"2015","journal-title":"Pulm Circ"},{"key":"key-10.4103\/1995-705X.254347-51","first-page":"547","volume-title":"Effects of ranolazine on exercise capacity, right ventricular indices, and hemodynamic characteristics in pulmonary arterial hypertension: A pilot study","author":"Khan","year":"2015","journal-title":"Pulm Circ"},{"key":"key-10.4103\/1995-705X.254347-52","first-page":"69","volume-title":"Long-term administration of ranolazine attenuates diastolic dysfunction and adverse myocardial remodeling in a model of heart failure with preserved ejection fraction","author":"De","year":"2016","journal-title":"Int J Cardiol"},{"key":"key-10.4103\/1995-705X.254347-53","first-page":"741","volume-title":"Effects of ranolazine on left ventricular regional diastolic function in patients with ischemic heart disease","author":"Hayashida","year":"1994","journal-title":"Cardiovasc Drugs Ther"},{"key":"key-10.4103\/1995-705X.254347-54","first-page":"115","volume-title":"RAnoLazIne for the treatment of diastolic heart failure in patients with preserved ejection fraction: The RALI-DHF proof-of-concept study","author":"Maier","year":"2013","journal-title":"JACC Heart Fail"},{"key":"key-10.4103\/1995-705X.254347-55","unstructured":"Maier LS. Ranolazine in Diastolic Heart Failure (RALI-DHF); 2010. Available from: https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01163734. [Last accessed on 2017 Oct 29]."},{"key":"key-10.4103\/1995-705X.254347-56","first-page":"426","volume-title":"Ranolazine for the treatment of heart failure with preserved ejection fraction: Background, aims, and design of the RALI-DHF study","author":"Jacobshagen","year":"2011","journal-title":"Clin Cardiol"},{"key":"key-10.4103\/1995-705X.254347-57","first-page":"66","volume-title":"Ranolazine preserves and improves left ventricular ejection fraction and autonomic measures when added to guideline-driven therapy in chronic heart failure","author":"Murray","year":"2014","journal-title":"Heart Int"},{"key":"key-10.4103\/1995-705X.254347-58","first-page":"1440","volume-title":"Effect of ranolazine on left ventricular dyssynchrony in patients with coronary artery disease","author":"Venkataraman","year":"2012","journal-title":"Am J Cardiol"},{"key":"key-10.4103\/1995-705X.254347-59","first-page":"1333","volume-title":"Targeting fatty acid and carbohydrate oxidation \u2013 A novel therapeutic intervention in the ischemic and failing heart","author":"Jaswal","year":"2011","journal-title":"Biochim Biophys Acta"},{"key":"key-10.4103\/1995-705X.254347-60","first-page":"88","volume-title":"Ranolazine in the prevention of anthracycline cardiotoxicity","author":"Corradi","year":"2014","journal-title":"Pharmacol Res"},{"key":"key-10.4103\/1995-705X.254347-61","first-page":"3696","volume-title":"Effects of ranolazine in a model of doxorubicin-induced left ventricle diastolic dysfunction","author":"Cappetta","year":"2017","journal-title":"Br J Pharmacol"},{"key":"key-10.4103\/1995-705X.254347-62","first-page":"343","volume-title":"Pharmacology at work for cardio-oncology: Ranolazine to treat early cardiotoxicity induced by antitumor drugs","author":"Minotti","year":"2013","journal-title":"J Pharmacol Exp Ther"},{"key":"key-10.4103\/1995-705X.254347-63","first-page":"2032","volume-title":"Evaluation of the glycometabolic effects of ranolazine in patients with and without diabetes mellitus in the MERLIN-TIMI 36 randomized controlled trial","author":"Morrow","year":"2009","journal-title":"Circulation"},{"key":"key-10.4103\/1995-705X.254347-64","first-page":"1163","volume-title":"Effect of ranolazine on A1C and glucose levels in hyperglycemic patients with non-ST elevation acute coronary syndrome","author":"Chisholm","year":"2010","journal-title":"Diabetes Care"},{"key":"key-10.4103\/1995-705X.254347-65","first-page":"1189","volume-title":"Effect of ranolazine monotherapy on glycemic control in subjects with type 2 diabetes","author":"Eckel","year":"2015","journal-title":"Diabetes Care"},{"key":"key-10.4103\/1995-705X.254347-66","first-page":"463","volume-title":"Effect of ranolazine on glycaemic control in patients with type 2 diabetes treated with either glimepiride or metformin","author":"Pettus","year":"2016","journal-title":"Diabetes Obes Metab"},{"key":"key-10.4103\/1995-705X.254347-67","first-page":"127","volume-title":"Ranolazine improves insulin resistance in non-diabetic patients with coronary heart disease.A pilot study","author":"Caminiti","year":"2016","journal-title":"Int J Cardiol"},{"key":"key-10.4103\/1995-705X.254347-68","first-page":"2038","volume-title":"Evaluation of ranolazine in patients with type 2 diabetes mellitus and chronic stable angina: Results from the TERISA randomized clinical trial (Type 2 diabetes evaluation of ranolazine in subjects with chronic stable angina)","author":"Kosiborod","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"key-10.4103\/1995-705X.254347-69","first-page":"710","volume-title":"Open-label trial of ranolazine for the treatment of myotonia congenita","author":"Arnold","year":"2017","journal-title":"Neurology"},{"key":"key-10.4103\/1995-705X.254347-70","first-page":"481","volume-title":"Ranolazine injection into coronary or femoral arteries exerts marked, transient regional vasodilation without systemic hypotension in an intact porcine model","author":"Nieminen","year":"2011","journal-title":"Circ Cardiovasc Interv"},{"key":"key-10.4103\/1995-705X.254347-71","first-page":"361","volume-title":"A pilot study of ranolazine in patients with intermittent claudication","author":"Ma","year":"2006","journal-title":"Int Angiol"},{"key":"key-10.4103\/1995-705X.254347-72","unstructured":"Supervised Treadmill Exercise and Ranolazine for Intermittent Claudication of Lower Extremities (STERILE, NCT00914316). Available from: https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT00914316. [Last accessed on 2017 Oct 29]."},{"key":"key-10.4103\/1995-705X.254347-73","first-page":"320","volume-title":"Sodium channel slow inactivation as a therapeutic target for myotonia congenita","author":"Novak","year":"2015","journal-title":"Ann Neurol"},{"key":"key-10.4103\/1995-705X.254347-74","doi-asserted-by":"crossref","unstructured":"Coppini R, Mazzoni L, Ferrantini C, Gentile F, Pioner JM, Laurino A, et al. Ranolazine prevents phenotype development in a mouse model of hypertrophic cardiomyopathy. Circ Heart Fail 2017;10. pii: e003565.","DOI":"10.1161\/CIRCHEARTFAILURE.116.003565"},{"key":"key-10.4103\/1995-705X.254347-75","first-page":"575","volume-title":"Late sodium current inhibition reverses electromechanical dysfunction in human hypertrophic cardiomyopathy","author":"Coppini","year":"2013","journal-title":"Circulation"},{"key":"key-10.4103\/1995-705X.254347-76","first-page":"222","volume-title":"Regulation of intracellular Na(+) in health and disease: Pathophysiological mechanisms and implications for treatment","author":"Coppini","year":"2013","journal-title":"Glob Cardiol Sci Pract"},{"key":"key-10.4103\/1995-705X.254347-77","first-page":"297","volume-title":"Management of refractory symptoms in hypertrophic cardiomyopathy with restrictive pathophysiology: Novel perspectives for ranolazine","author":"Tomberli","year":"2012","journal-title":"G Ital Cardiol (Rome)"}],"container-title":["Heart Views"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T13:45:10Z","timestamp":1786715110000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/HEARTVIEWS.HEARTVIEWS_18_18"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018]]},"references-count":77,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018]]}},"alternative-id":["254347"],"URL":"https:\/\/doi.org\/10.4103\/heartviews.heartviews_18_18","relation":{},"ISSN":["1995-705X"],"issn-type":[{"value":"1995-705X","type":"print"}],"subject":[],"published":{"date-parts":[[2018]]}}}